[go: up one dir, main page]

AR079050A1 - Compuestos benzoimidazolicos y sus usos - Google Patents

Compuestos benzoimidazolicos y sus usos

Info

Publication number
AR079050A1
AR079050A1 ARP100104240A ARP100104240A AR079050A1 AR 079050 A1 AR079050 A1 AR 079050A1 AR P100104240 A ARP100104240 A AR P100104240A AR P100104240 A ARP100104240 A AR P100104240A AR 079050 A1 AR079050 A1 AR 079050A1
Authority
AR
Argentina
Prior art keywords
compound
formula
benzoimidazolic
compounds
salt
Prior art date
Application number
ARP100104240A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR079050A1 publication Critical patent/AR079050A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

También se refiere a composiciones farmacéuticas y a kits que comprenden un compuesto de este tipo, a los usos de un compuesto de este tipo (incluidos, por ejemplo, los métodos de tratamiento y los preparados farmacéuticos), a los procesos para fabricar un compuesto de este tipo y a los intermedios empleados en tales procesos. Reivindicacion 1: El compuesto de Formula 1 o una sal de este, donde el compuesto de Formula 1 se corresponde con (1). Reivindicacion 2: Un compuesto o una sal de este de acuerdo con la reivindicacion 1, donde el compuesto se corresponde con la Formula (2). Reivindicacion 3: Un compuesto o una sal de este de acuerdo con la reivindicacion 1, donde el compuesto se corresponde con la Formula (3).
ARP100104240A 2009-11-18 2010-11-17 Compuestos benzoimidazolicos y sus usos AR079050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26226309P 2009-11-18 2009-11-18

Publications (1)

Publication Number Publication Date
AR079050A1 true AR079050A1 (es) 2011-12-21

Family

ID=44059844

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104240A AR079050A1 (es) 2009-11-18 2010-11-17 Compuestos benzoimidazolicos y sus usos

Country Status (16)

Country Link
US (1) US8530467B2 (es)
EP (1) EP2501697B1 (es)
JP (1) JP5657018B2 (es)
KR (1) KR20120113709A (es)
CN (1) CN102741245B (es)
AR (1) AR079050A1 (es)
AU (1) AU2010322478B2 (es)
BR (1) BR112012011518B8 (es)
CA (1) CA2777746C (es)
ES (1) ES2442797T3 (es)
IN (1) IN2012DN03391A (es)
MX (1) MX2012005329A (es)
RU (1) RU2542582C2 (es)
TW (1) TW201121957A (es)
UY (1) UY33037A (es)
WO (1) WO2011062550A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158117A1 (en) * 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
DK3381917T3 (da) * 2013-01-31 2021-10-18 Bellus Health Cough Inc Imidazopyridinforbindelser og anvendelser deraf
WO2015093586A1 (ja) * 2013-12-20 2015-06-25 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物およびその中間体の製造方法
WO2016004358A1 (en) * 2014-07-03 2016-01-07 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
AU2019416589B2 (en) * 2018-12-29 2023-04-06 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound intermediate, preparation method therefor and application thereof
CA3131312A1 (en) 2019-02-25 2020-09-03 Bellus Health Cough Inc. Treatment with p2x3 modulators
IL295393A (en) * 2020-02-14 2022-10-01 Bellus Health Cough Inc P2x3 modulators
KR20230051209A (ko) * 2020-08-13 2023-04-17 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 벤즈이미다졸 유도체, 이의 제조 방법 및 이의 의학적 용도
TW202227458A (zh) * 2020-12-04 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 含有稠合三環的化合物及其醫藥用途
CN114478508A (zh) * 2021-12-31 2022-05-13 淮北师范大学 一种苯并咪唑化合物的结晶形式
WO2023151660A1 (zh) * 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 一种p2x3受体拮抗剂的结晶形式及其制备方法
WO2023151658A1 (zh) * 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 一种p2x3受体拮抗剂的可药用盐及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026A (en) * 1849-01-09 Cast-iron car-wheel
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
TR200500745T2 (tr) 1999-02-10 2005-05-23 Astrazeneca Ab Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
SI1249450T1 (sl) * 2000-01-17 2008-04-30 Teijin Pharma Ltd Derivati benzimidola kot inhibitorji humane kimaze
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
WO2002004434A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
RU2374234C2 (ru) * 2004-09-24 2009-11-27 Астразенека Аб Бензимидазольные производные, содержащие их композиции, их получение и применение
MX2009009416A (es) * 2007-03-02 2009-09-11 Schering Corp Derivados de bencimidazol y sus metodos de uso.
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
JP2011502148A (ja) * 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト

Also Published As

Publication number Publication date
ES2442797T3 (es) 2014-02-13
JP5657018B2 (ja) 2015-01-21
US8530467B2 (en) 2013-09-10
AU2010322478B2 (en) 2013-11-14
AU2010322478A1 (en) 2012-05-31
IN2012DN03391A (es) 2015-10-23
CA2777746A1 (en) 2011-05-26
BR112012011518B1 (pt) 2020-03-10
US20120289504A1 (en) 2012-11-15
WO2011062550A1 (en) 2011-05-26
EP2501697A1 (en) 2012-09-26
UY33037A (es) 2011-06-30
RU2012124268A (ru) 2013-12-27
BR112012011518A2 (pt) 2016-06-28
TW201121957A (en) 2011-07-01
RU2542582C2 (ru) 2015-02-20
BR112012011518B8 (pt) 2023-01-10
CN102741245A (zh) 2012-10-17
EP2501697A4 (en) 2013-04-24
JP2013511517A (ja) 2013-04-04
CN102741245B (zh) 2014-11-05
EP2501697B1 (en) 2013-10-23
CA2777746C (en) 2019-05-14
KR20120113709A (ko) 2012-10-15
MX2012005329A (es) 2012-05-29

Similar Documents

Publication Publication Date Title
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
UY32490A (es) Inhibidores de beta-secretasa
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
UY32062A (es) Inhibidores de beta-secretasa
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
CR11857A (es) Compuestos pirazolicos 436
CR10479A (es) Modulares bencimidazolicos de vr1
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
CO6761373A2 (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
GT200600117A (es) Nuevos compuestos farmaceuticos
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii

Legal Events

Date Code Title Description
FB Suspension of granting procedure